ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Banerjee, Arindam ^a   Wu, Zheng Sheng ^b,c,d   Qian, PengXu ^b   Kang, Jian ^a   Pandey, Vijay ^e   Liu, Dong Xu ^a   Zhu, Tao ^b   Lobie, Peter E ^a,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIN; ESTROGEN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; ARTN PROTEIN, HUMAN; NERVE PROTEIN; NUCLEAR PROTEIN; TWIST1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CARCINOGENICITY; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; TUMOR EMBOLISM; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL MOTION; CELL TRANSFORMATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MORTALITY; NUDE MOUSE; PROTEIN BINDING; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; TWIST TRANSCRIPTION FACTOR;

EID: 80355132593     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3054     Document Type: Article

References (53)

1. Li Y, Brown PH. Prevention of ER-negative breast cancer. Recent Results Cancer Res 2009, 181:121-134. 10.1007/978-3-540-69297-3_13, 19213564.
2. Putti TC, El-Rehim DMA, Rakha EA, Paish CE, Lee AHS, Pinder SE, Ellis IO. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2004, 18:26-35.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
4. Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research 2010, 12:R68. 10.1186/bcr2635, 3096954, 20813035.
5. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010, 107:15449-15454. 10.1073/pnas.1004900107, 2932589, 20713713.
6. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002, 3:383-394. 10.1038/nrn812, 11988777.
7. Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, Lobie PE. Artemin is oncogenic for human mammary carcinoma cells. Oncogene 2009, 28:2034-2045. 10.1038/onc.2009.66, 19363524.
8. Kang J, Qian PX, Pandey V, Perry JK, Miller LD, Liu ET, Zhu T, Liu DX, Lobie PE. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene 2010, 29:3228-3240. 10.1038/onc.2010.71, 20305694.
9. Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin Z, Wu ZS, Liu DX, Zhu T, Lobie PE. Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. Endocrinology 2010, 151:909-920. 10.1210/en.2009-0979, 20118197.
10. Tang J-Z, Kong X-J, Kang J, Fielder GC, Steiner M, Perry JK, Wu Z-S, Yin Z, Zhu T, Liu D-X, Lobie PE. Artemin-stimulated progression of human non small cell lung carcinoma is mediated by BCL2. Molecular Cancer Therapeutics 2010, 9:1697-1708. 10.1158/1535-7163.MCT-09-1077, 20530713.
11. Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Buchler MW, Friess H. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 2006, 244:274-281. 10.1097/01.sla.0000217642.68697.55, 1602177, 16858191.
12. Lee YM, Park T, Schulz RA, Kim Y. Twist-mediated activation of the NK-4 homeobox gene in the visceral mesoderm of Drosophila requires two distinct clusters of E-box regulatory elements. J Biol Chem 1997, 272:17531-17541. 10.1074/jbc.272.28.17531, 9211899.
13. Yin Z, Xu XL, Frasch M. Regulation of the twist target gene tinman by modular cis-regulatory elements during early mesoderm development. Development 1997, 124:4971-4982.
14. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008, 14:79-89. 10.1016/j.ccr.2008.06.005, 18598946.
15. Puisieux A, Valsesia-Wittmann S, Ansieau S. A twist for survival and cancer progression. Br J Cancer 2006, 94:13-17. 10.1038/sj.bjc.6602876, 2361066, 16306876.
16. Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 2010, 29:3173-3184. 10.1038/onc.2010.92, 20383196.
17. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939. 10.1016/j.cell.2004.06.006, 15210113.
18. Fu J, Qin L, He T, Qin J, Hong J, Wong J, Liao L, Xu J. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res 2011, 21:275-289. 10.1038/cr.2010.118, 20714342.
19. Zhang Y, Su H, Rahimi M, Tochihara R, Tang C. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer 2009, 125:2021-2028. 10.1002/ijc.24540, 2855543, 19588487.
20. Clarke R, Brunner N. Acquired estrogen independence and antiestrogen resistance in breast cancer: estrogen receptor driven phenotypes?. Trends Endocrinol Metab 1996, 7:291-301. 10.1016/S1043-2760(96)00127-0, 18406762.
21. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
22. Pandey V, Perry JK, Mohankumar KM, Kong X-J, Liu S-M, Wu Z-S, Mitchell MD, Zhu T, Lobie PE. Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 2008, 149:3909-3919. 10.1210/en.2008-0286, 2488240, 18450952.
23. Tang J-Z, Zuo Z-H, Kong X-J, Steiner M, Yin Z, Perry JK, Zhu T, Liu D-X, Lobie PE. Signal Transducer and Activator of Transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology 2010, 151:43-55. 10.1210/en.2009-0651, 19966185.
24. Park JS, Kim KM, Kim MH, Chang HJ, Baek MK, Kim SM, Jung YD. Resveratrol inhibits tumor cell adhesion to endothelial cells by blocking ICAM-1 Expression. Anticancer Research 2009, 29:355-362.
25. Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009. 10.1038/nature08021, 2698953, 19421193.
26. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
27. Hu J, Verkman AS. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J 2006, 20:1892-1894. 10.1096/fj.06-5930fje, 16818469.
28. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
29. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009, 15:2657-2665. 10.1158/1078-0432.CCR-08-2372, 19336515.
30. Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SAW. Metastasis-associated protein 2 is a repressor of estrogen receptor {alpha} whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol 2006, 20:2020-2035. 10.1210/me.2005-0063, 16645043.
31. Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Research 2007, 67:10296-10303. 10.1158/0008-5472.CAN-07-2173, 17974971.
32. Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H, Le Bourhis X. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009, 28:1960-1970. 10.1038/onc.2009.61, 19330021.
33. Gort EH, van Haaften G, Verlaan I, Groot AJ, Plasterk RHA, Shvarts A, Suijkerbuijk KPM, van Laar T, van der Wall E, Raman V, van Diest PJ, Tijsterman M, Vooijs M. The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2[alpha]. Oncogene 2007, 27:1501-1510.
34. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang L-H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Research 2007, 67:1979-1987. 10.1158/0008-5472.CAN-06-1479, 17332325.
35. Correll PH, Morrison AC, Lutz MA. Receptor tyrosine kinases and the regulation of macrophage activation. J Leukoc Biol 2004, 75:731-737.
36. Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, Han J, Luo T, Wen F, Wu X. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochemical and Biophysical Research Communications 2007, 358:925-930. 10.1016/j.bbrc.2007.05.023, 17512904.
37. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005, 207:139-146. 10.1002/path.1829, 16088978.
38. Chen J-Q, Russo J. ER[alpha]-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2009, 1796:162-175.
39. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993, 4:193-201.
40. Dickson RB, McManaway ME, Lippman ME. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 1986, 232:1540-1543. 10.1126/science.3715461, 3715461.
41. Miyagawa S, Katsu Y, Watanabe H, Iguchi T. Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol. Oncogene 2004, 23:340-349. 10.1038/sj.onc.1207207, 14647453.
42. Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 2002, 277:45695-45703. 10.1074/jbc.M208092200, 12244117.
43. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, Wong YC. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004, 23:474-482. 10.1038/sj.onc.1207128, 14724576.
44. Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S, Huang J. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 2010, 31:1376-1380. 10.1093/carcin/bgq120, 20530554.
45. Zhao M, Mueller B, DiScipio R, Schraufstatter I. Akt plays an important role in breast cancer cell chemotaxis to CXCL12. Breast Cancer Research and Treatment 2008, 110:211-222. 10.1007/s10549-007-9712-7, 17687643.
46. Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Kikkawa F. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 2007, 96:314-320. 10.1038/sj.bjc.6603533, 2360014, 17211477.
47. Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, Nawa A, Nomura S, Kikkawa F. Twist expression in patients with cervical cancer is associated with poor disease outcome. Annals of Oncology 2008, 19:81-85. 10.1093/annonc/mdn316, 17925286.
48. Xie F, Li K, Ouyang X. Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clin Exp Metastasis 2009, 26:1025-1032. 10.1007/s10585-009-9292-5, 19816777.
49. Vesuna F, Lisok A, Kimble B, Raman V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 2009, 11:1318-1328. 2794513, 20019840.
50. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313. 10.1158/0008-5472.CAN-08-2741, 2819227, 19190339.
51. Bovee JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, van den Broek LJ, Taminiau AH, Cornelisse CJ, Hogendoorn PC. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer 1999, 26:237-246. 10.1002/(SICI)1098-2264(199911)26:3<237::AID-GCC8>3.0.CO;2-L, 10502322.
52. Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JW, van de Vijver MJ. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys 1999, 45:73-83. 10.1016/S0360-3016(99)00158-3, 10477009.
53. Parl FF, Schmidt BP, Dupont WD, Wagner RK. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984, 54:2237-2242. 10.1002/1097-0142(19841115)54:10<2237::AID-CNCR2820541029>3.0.CO;2-V, 6488142.